Table 1 Participant demographics
Trial number | Age range | Factor prior to gene therapy | Current factor level*• | Haemophilia type | Years since gene therapy treatment† | Immunosuppression required |
|---|---|---|---|---|---|---|
Exi01 | 45–54 | EHL | 1.37 | Haem A | 1 | Yes |
Exi02 | 18–24 | EHL | 0.21 | Haem A | 1 | Yes |
Exi03 | 25–34 | SHL | 0.50 | Haem A | 1 | Yes |
Exi04 | 45–54 | EHL | 0.90 | Haem B | 1 | Yes |
Exi05 | 25–34 | SHL | 0.11 | Haem A | 5 | Yes |
Exi06 | 25–34 | SHL | 0.05 | Haem A | 3 | Yes |
Exi07 | 35–44 | SHL | 0.06 | Haem A | 1 | Yes |
Exi08 | 35–44 | SHL | 0.02 | Haem B | 9 | No |
Exi09 | 75–84 | SHL | 0 | Haem B | 10 | No |
Exi10 | 65–74 | SHL | 0.25 | Haem A | 2 | Yes |
Exi11 | 35–44 | SHL | 0 | Haem B | 10 | No |
Exi12 | 25–34 | SHL | 0.07 | Haem A | 3 | Yes |
Exi13 | 55–64 | SHL | 0.13 | Haem A | 2 | Yes |
Exi14 | 25–34 | SHL | 0.40 | Haem B | 4 | Yes |
Exi15 | 35–44 | SHL | 1.20 | Haem A | 1 | Yes |
Exi16 | 25–34 | EHL | 0.06 | Haem A | 3 | Yes |